Safety of PD-1 Inhibitors in Squamous Non-Small Cell Lung Cancer

The panelists, Benjamin Levy, MD; Edward S. Kim, MD, FACP; and Paul K. Paik, MD, identify patients with squamous non-small cell lung cancer who may benefit from immune checkpoint inhibitors and the management of any related toxicity.

• kategori